1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  6. QuickLinks
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  6. QuickLinks
  1. Launch

ILC Therapeutics Ltd

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2020

Location

Glasgow UK

Primary Industry

Biotechnology

About

Based in Lanarkshire, UK, and founded in 2020, ILC Therapeutics operates as a biotechnology company that develops novel peptide therapeutics intended to find a cure against COVID-19, ARDS, Oncology, Psoriasis, and Atopic Dermatitis. In May 2021, ILC Therapeutics raised GBP 3.5 million in venture funding from Scottish Enterprise and EOS Technology Investment Syndicate, and individual investors and Management investors also participated in the round. ILC Therapeutics develops a new class of interferon medicines called hybrid interferons that take features of natural interferon subtypes and combine them into one new hybrid interferon molecule that is designed to deliver enhanced efficacy and improved safety over a range of high-value therapeutic areas, enabling healthcare professionals to improve patient outcomes and find a cure against diseases. The company plans to use the funding to accelerate the development of Alfacyte – its lead hybrid interferon designed to combat viral infections including Covid.
Current Investors
EOS Technology Investment Syndicate, Scottish Enterprise, Medical Incubator Japan K.K.

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.ilctherapeutics.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.